Idexx Laboratories (IDXX) Cash & Current Investments (2009 - 2026)

Idexx Laboratories has reported Cash & Current Investments for 18 years, with the latest figure at $196.9 million in Q2 2026.

• On a quarterly basis, Cash & Current Investments rose 19.65% year-over-year to $196.9 million in Q2 2026; TTM through Jun 2026 was $196.9 million, a 19.65% increase from a year earlier, with the FY2025 full-year figure at $180.1 million, down 37.53% from the prior year.
• Cash & Current Investments was $196.9 million for Q2 2026 at Idexx Laboratories, down from $200.5 million in the prior quarter.
• The five-year high for Cash & Current Investments was $453.9 million in Q4 2023, with the low at $99.2 million in Q3 2022.
• Average Cash & Current Investments over 5 years is $226.2 million, with a median of $198.7 million recorded in 2026.
• The sharpest annual moves came in 2023 and 2025: Cash & Current Investments jumped 303.33% in 2023, then sank 59.01% in 2025.
• Over 5 years, Cash & Current Investments stood at $112.5 million in 2022, then soared by 303.33% to $453.9 million in 2023, then slumped by 36.5% to $288.3 million in 2024, then plunged by 37.53% to $180.1 million in 2025, then rose by 9.36% to $196.9 million in 2026.
• The last three Cash & Current Investments figures came in at $196.9 million (Q2 2026), $200.5 million (Q1 2026), and $180.1 million (Q4 2025), per Business Quant data.